The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: SCTV01COther: AdjuvantOther: Saline
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 478
- Registration Number
- NCT05148091
- Locations
- 🇨🇳
PetroChina Central Hospital, Langfang, Hebei, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Hunan Provincial Center for Disease Control And Prevention, Changsha, Hunan, China
A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years
Phase 2
- Conditions
- RandomizedInterventionalPrevention
- Interventions
- Biological: SCT1000Biological: Gardasil®9Biological: Gardasil®Other: placebo
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 1800
- Registration Number
- NCT05060484
- Locations
- 🇨🇳
Guanyun Country CDC, Nanjing, Jiangsu, China
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
Phase 1
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: SCTV01COther: Placebo
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05043285
- Locations
- 🇦🇪
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
Phase 1
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: SCTV01COther: Placebo
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05043311
- Locations
- 🇦🇪
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years
Phase 1
- Conditions
- HPV Infection Vaccine Safety SCT1000
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT04921111
- Locations
- 🇨🇳
Guanyun Country CDC, Nanjing, Jiangsu, China
To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 690
- Registration Number
- NCT04709328
The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care
Phase 2
- Conditions
- Covid19
- Interventions
- Biological: SCTA01 PlaceboBiological: SCTA01
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT04683328
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT04644185
- Locations
- 🇵🇪
SCT study site, Lima, Peru
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04564937
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 405
- Registration Number
- NCT04560894
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath